Illinois Medicaid Filled Nearly 1 Million Prescriptions for Leading GLP-1 Drugs Before the FDA’s Vision Loss Warning
Announcement from a bar association
Headline as published by Illinois Lawyer Now (ISBA) on Nov 13, 2026; collected by the wire Nov 13, 2026, 8:00 PM ET.
Illinois Medicaid paid for 993,119 prescriptions for nine leading GLP-1 drugs between 2022 and 2025, at a gross cost of $1.1 billion. Every one was filled before November 9, 2026, when the FDA ordered manufacturers to add a warning about a rare form of permanent vision loss called NAION. Ankin Law analyzed four years of... Continue Reading
Coverage
Named in this story
- AgencyU.S. Food and Drug AdministrationMatched on
FDA
- FirmAnkin LawSeveral firms in our index share this name, so no single profile is linked.
- MDLMDL 3163 · GLP-1 Vision Loss (NAION)Matched on
NAION
Topics
- Mass torts and MDLsMatched on
NAION
Explore the named firms, organizations and MDL dockets above. Sources and method
MDL No. 3163
GLP-1 Vision Loss (NAION)
IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation
- Transferee judge
- Karen S. Marston
- Court
- Eastern District of Pennsylvania
- Actions pending
- 247
Per the JPML pending-dockets report of October 1, 2026.